Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential benefits of allowing men who require Hormone Replacement Therapy in the form of testosterone to be added to the HRT Prescription Prepayment Certificate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The hormone replacement therapy prescription prepayment certificate (HRT PPC) was introduced to support women in accessing hormone replacement therapy medicines on the National Health Service as part of their care during menopause. The equalities impact assessment is available at the following link:
Testosterone products are not in scope for the HRT PPC because, even though they can be used "off-label" to treat menopause symptoms, they are not licensed for this purpose. No United Kingdom licensed testosterone products for the treatment of menopause symptoms have been launched in the UK.
Anyone can purchase the HRT PPC if they feel that it is the most appropriate product for them. The three-month or 12-month PPC, which cover all medicines prescribed on the NHS, may be more appropriate for patients who are prescribed medicines not covered by the HRT PPC.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the NHS 10 year plan commitment to carry out DNA mapping on all new born babies, what steps he is taking to protect personal health data.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan set out an ambition to “implement universal genomic testing” within the next decade. Delivering against this ambition will be subject to evidence gathered through the Generation Study, delivered by Genomics England and the National Health Service. This research programme is evaluating the effectiveness of using whole genome sequencing to test 100,000 newborns for genetic mutations associated with more than 200 rare genetic conditions. The study is asking parents for consent to securely store their baby’s genomic and health data, with strict safeguards to protect identities. With consent, data is stored securely in the National Genomic Research Library, run by Genomics England, to support research on the causes of genetic conditions. Access is tightly controlled, overseen by an independent committee, and only permitted within a secure environment.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the timetable is for implementing the National Screening Committee’s In-Service Evaluation of newborn screening for spinal muscular atrophy; what the duration of the evaluation will be; and when the NSC expects to reach a recommendation on whether SMA should be added to the newborn blood spot screening programme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
On all aspects of population and targeted screening, Ministers are advised by the UK National Screening Committee (UK NSC).
The UK NSC recommended an in-service evaluation (ISE) of newborn blood spot screening for spinal muscular atrophy (SMA) in National Health Services in 2023. Since then, the SMA Newborn Screening ISE Partnership Board was set up to plan and develop work to shape the ISE, and progress is being made. This includes planning the duration of the ISE and planning for newborn laboratories to screen blood spot samples for SMA. The laboratories in England that will form part of the ISE are under consideration by the SMA partnership board led by NHS England. The researchers and the National Institute for Health and Research (NIHR) will be responsible for determining the number of babies and services that will be required to answer the research questions.
Earlier in the year, the NIHR published their Health Technology Assessment research brief to appoint researchers for this work. Applications closed at the end of September 2025, and final funding decisions are expected in spring 2026. A decision on the shape and roll out of the ISE will be made after the research call process has concluded.
A recommendation by the UK NSC on newborn screening for SMA is expected following the conclusion of an ISE, which is needed to answer several outstanding questions related to the implementation of a screening programme for SMA.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to expand prescribing of GLP-1 medications beyond specialist weight-management services.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
National Institute for Health and Care Excellence (NICE) guidance on the first two GLP-1 medicines licensed for the treatment of obesity, namely liraglutide under various brand names and semaglutide with brand name Wegovy, restricted their use to specialist weight management services. These services are primarily delivered in secondary care.
NICE recommended that tirzepatide, with brand name Mounjaro, could be used for the treatment of obesity in eligible patients without a restriction on its setting. This means tirzepatide can be used in specialist weight management services but can also be prescribed in primary care by general practitioners (GPs) and other competent prescribers. From 23 June 2025, tirzepatide started to become available in primary care so the expansion beyond specialist services is underway.
Integrated care boards (ICBs) are the National Health Service organisations responsible for arranging the provision of health services within their area in line with local population need and taking account of relevant guidance. ICBs have had to develop new care pathways to ensure that patients can access these medicines via their GP with appropriate wraparound support. NHS England has been working closely with ICBs to support the safe and effective roll out of tirzepatide in primary care. It has identified the groups of people to be prioritised in each phase of the initial rollout; helped develop local treatment models; provided funding support and regular communication channels to ICBs; and set up an interim, centrally funded ‘wraparound care service’, known as the ‘Healthier You: Behavioural Support for Obesity Prescribing’, for patients to be referred into, with a procurement underway for a longer-term offer.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has had recent discussions with Eli Lilly on the cost of Mounjaro.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has held various discussions with Eli Lilly regarding the recent list price increase of Mounjaro. NHS England has worked with Eli Lilly to ensure the list price increase will not affect National Health Service commissioning of tirzepatide in England as a treatment for eligible diabetes and obesity patients in the NHS.
We remain committed to the rollout of this medicine as a weight loss treatment based on clinical priority. This will enable 220,000 eligible people to access the medication over the first three years. The initial eligibility criteria will be for people with a body mass index of 40 or more in addition to four or more qualifying comorbidities.
Scotland, Wales and Northern Ireland have also entered equivalent agreements to maintain their current commissioning approaches.
Pricing in the private market is a matter for Eli Lilly and for private providers. Private patients who are impacted by price increases should discuss any concerns with their private provider. This includes their options regarding payment plans, alternative treatments, and/or stopping or tapering off their current medication. Eli Lilly is working with private providers to support continued patient access.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the 10-Year Plan for Health promotes equitable access to (a) palliative and (b) end of life care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
One of the three ‘shifts’ that the 10 Year Health Plan will deliver is around the Government’s determination to shift healthcare out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift and were highlighted in the plan as being an integral part of neighbourhood teams.
I have tasked officials to look at how to improve the access, quality, and sustainability of all- age palliative and end of life care in line with the 10 Year Health Plan.
Officials will present further proposals to ministers over the coming months, outlining the drivers and incentives that are required in palliative care and end of life care to enable the shift from hospital to community, including as part of neighbourhood health teams.
To support integrated care boards (ICBs) in the commissioning of palliative care and end of life care services, NHS England has published statutory guidance and service specifications. The guidance makes specific reference to commissioners defining how their services will meet population needs 24/7 and includes a priority action for ensuring that staff, patients, and carers can access the care and advice they need, whatever time of day.
National Institute for Health and Care Excellence (NICE) guidance on the service delivery of end of life care for adults also includes recommendations about 24/7 access to care. Although NICE guidance is not mandatory, there is an expectation that commissioners and service providers take the guidelines into account when making decisions about how to best meet the needs of their local communities.
The Government and the National Health Service will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to help ensure that services remove variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to introduce a 24/7 single point of access for palliative and end of life care (a) advice, (b) guidance and (c) support, following the publication of the 10-Year Plan for Health.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
One of the three ‘shifts’ that the 10 Year Health Plan will deliver is around the Government’s determination to shift healthcare out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift and were highlighted in the plan as being an integral part of neighbourhood teams.
I have tasked officials to look at how to improve the access, quality, and sustainability of all- age palliative and end of life care in line with the 10 Year Health Plan.
Officials will present further proposals to ministers over the coming months, outlining the drivers and incentives that are required in palliative care and end of life care to enable the shift from hospital to community, including as part of neighbourhood health teams.
To support integrated care boards (ICBs) in the commissioning of palliative care and end of life care services, NHS England has published statutory guidance and service specifications. The guidance makes specific reference to commissioners defining how their services will meet population needs 24/7 and includes a priority action for ensuring that staff, patients, and carers can access the care and advice they need, whatever time of day.
National Institute for Health and Care Excellence (NICE) guidance on the service delivery of end of life care for adults also includes recommendations about 24/7 access to care. Although NICE guidance is not mandatory, there is an expectation that commissioners and service providers take the guidelines into account when making decisions about how to best meet the needs of their local communities.
The Government and the National Health Service will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to help ensure that services remove variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to provide funding certainty to hospices beyond this financial year, in the context of the 10-year plan for palliative and end-of-life care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
One of the three ‘shifts’ that the 10 Year Health Plan will deliver is around the Government’s determination to shift healthcare out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift and were highlighted in the plan as being an integral part of neighbourhood teams.
I have tasked officials to look at how to improve the access, quality, and sustainability of all- age palliative and end of life care in line with the 10 Year Health Plan.
Officials will present further proposals to ministers over the coming months, outlining the drivers and incentives that are required in palliative care and end of life care to enable the shift from hospital to community, including as part of neighbourhood health teams.
To support integrated care boards (ICBs) in the commissioning of palliative care and end of life care services, NHS England has published statutory guidance and service specifications. The guidance makes specific reference to commissioners defining how their services will meet population needs 24/7 and includes a priority action for ensuring that staff, patients, and carers can access the care and advice they need, whatever time of day.
National Institute for Health and Care Excellence (NICE) guidance on the service delivery of end of life care for adults also includes recommendations about 24/7 access to care. Although NICE guidance is not mandatory, there is an expectation that commissioners and service providers take the guidelines into account when making decisions about how to best meet the needs of their local communities.
The Government and the National Health Service will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to help ensure that services remove variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the 10-Year Plan for Health, if he will publish further detail on proposals to increase the provision of palliative and end of life care in community settings.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
One of the three ‘shifts’ that the 10 Year Health Plan will deliver is around the Government’s determination to shift healthcare out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift and were highlighted in the plan as being an integral part of neighbourhood teams.
I have tasked officials to look at how to improve the access, quality, and sustainability of all- age palliative and end of life care in line with the 10 Year Health Plan.
Officials will present further proposals to ministers over the coming months, outlining the drivers and incentives that are required in palliative care and end of life care to enable the shift from hospital to community, including as part of neighbourhood health teams.
To support integrated care boards (ICBs) in the commissioning of palliative care and end of life care services, NHS England has published statutory guidance and service specifications. The guidance makes specific reference to commissioners defining how their services will meet population needs 24/7 and includes a priority action for ensuring that staff, patients, and carers can access the care and advice they need, whatever time of day.
National Institute for Health and Care Excellence (NICE) guidance on the service delivery of end of life care for adults also includes recommendations about 24/7 access to care. Although NICE guidance is not mandatory, there is an expectation that commissioners and service providers take the guidelines into account when making decisions about how to best meet the needs of their local communities.
The Government and the National Health Service will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to help ensure that services remove variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.
Asked by: Sarah Hall (Labour (Co-op) - Warrington South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of waiting times for cardiac care in the North West.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Tackling the waiting list is a top priority for the Government. This includes decreasing wait times for those accessing cardiac care. We have exceeded our pledge to deliver over two million more elective care appointments. More than double that number, or 5.2 million more appointments, have now been delivered in England.
On 6 January 2025, NHS England published the new Elective Reform Plan. This sets out a whole system approach to delivering on the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the National Health Service constitutional standard, by March 2029.
As of the end of July 2025, compared with the end of June 2024, the overall number of people waiting for cardiac treatment in the North West has fallen by 7,536. However, performance against the 18-week target has decreased by 0.3 percentage points over the same period, namely 56.2% in June 2024 and 55.9% in July 2025.